Secondary brain injury is a frequent event in TBI patients.
These events greatly influence prognosis and are potentially preventable.
Our understanding of secondary brain injury mechanisms and physiologic responses to treatment is evolving.
This study examined the effects of craniosacral therapy (CST) on heart rate variability (HRV) in 31 patients with subjective discomforts. HRV was measured before and after a 30-minute control rest period and a 30-minute CST session on consecutive days using a mobile device. Standard deviation of heart rate intervals (SDNN) and total power (TP), indicators of autonomic nervous system activity, increased significantly after CST but not the control rest. Heart rate also decreased significantly after CST compared to rest. However, interactions between treatment and HRV changes were not fully statistically significant. The study provides preliminary evidence that CST may positively influence autonomic nervous system regulation.
'Rare TACS/Neurostimulation' - Dr Manjit Matharu (Clinical Lead of the Headache Group, a senior lecturer at The Institute of Neurology and Honorary Consultant Neurologist at The National Hospital for Neurology and Neurosurgery) from the Cumbria Neuroscience Conference
This document discusses hypothermia as a potential treatment for traumatic brain injury (TBI). It provides an overview of the mechanisms by which hypothermia may be neuroprotective after TBI. It then reviews the results of numerous clinical trials that have investigated hypothermia for TBI, finding no clear evidence of improved outcomes with hypothermia compared to normothermia. The document concludes by discussing reasons for the lack of evidence and considerations for future trials, as the role of hypothermia in TBI remains uncertain.
1) The study used high-resolution MRI to measure the dimensions of the cavernous sinus and surrounding structures in patients with cluster headache, chronic paroxysmal hemicrania, and controls.
2) They found that patients with cluster headache and chronic paroxysmal hemicrania had wider skulls than controls. However, after adjusting for skull size, there were no differences in the dimensions of the cavernous sinus between patients and controls.
3) One finding was that probable cluster headache patients had a larger left-to-right pituitary diameter compared to controls, but pituitary volumes did not differ between groups. Overall, the study found no evidence that cavernous sinus dimensions are constitutionally narrow
Intraoperative Monitoring for Brain and Spinal Cord TumorsDhaval Shukla
Intraoperative monitoring (IOM) during brain and spinal surgeries aims to prevent new or worsened neurological deficits. While IOM is not based on class I evidence, controlled studies would be unethical given its effectiveness in predicting injuries. Studies show IOM reduces postoperative deficits compared to no monitoring. For glioma resections, IOM-guided resection allows safer maximal removal in eloquent areas, improving survival and quality of life. Awake craniotomy with IOM results in fewer deficits than general anesthesia. While false negatives and cost are challenges, IOM avoidance risks greater deficits and rehabilitation costs. IOM should be used for brain and spinal tumor resections when near critical structures.
1) Hypothermia has been proposed as a treatment for traumatic brain injury (TBI) to help reduce secondary brain damage.
2) Previous studies on hypothermia for TBI have shown mixed results, with some trials finding benefits and others finding no effect.
3) The author conducted a randomized controlled trial of 107 patients with severe TBI to study the effects of progesterone, hypothermia, or their combination on outcomes.
4) The trial found the best outcomes based on Glasgow Outcome Scale at 6 months in the hypothermia group, followed by the progesterone group, though the combination did not provide additional benefit over hypothermia alone.
1) Hypothermia has been proposed as a treatment for traumatic brain injury (TBI) to help reduce secondary brain damage.
2) Previous studies on hypothermia for TBI have shown mixed results, with some trials finding benefits and others finding no effect.
3) The author conducted a randomized controlled trial of 107 patients with severe TBI to study the effects of progesterone, hypothermia, or their combination on outcomes.
4) The trial found the best outcomes based on Glasgow Outcome Scale at 6 months in the hypothermia group, followed by the progesterone group, though the combination did not provide additional benefit over hypothermia alone.
This study examined the effects of craniosacral therapy (CST) on heart rate variability (HRV) in 31 patients with subjective discomforts. HRV was measured before and after a 30-minute control rest period and a 30-minute CST session on consecutive days using a mobile device. Standard deviation of heart rate intervals (SDNN) and total power (TP), indicators of autonomic nervous system activity, increased significantly after CST but not the control rest. Heart rate also decreased significantly after CST compared to rest. However, interactions between treatment and HRV changes were not fully statistically significant. The study provides preliminary evidence that CST may positively influence autonomic nervous system regulation.
'Rare TACS/Neurostimulation' - Dr Manjit Matharu (Clinical Lead of the Headache Group, a senior lecturer at The Institute of Neurology and Honorary Consultant Neurologist at The National Hospital for Neurology and Neurosurgery) from the Cumbria Neuroscience Conference
This document discusses hypothermia as a potential treatment for traumatic brain injury (TBI). It provides an overview of the mechanisms by which hypothermia may be neuroprotective after TBI. It then reviews the results of numerous clinical trials that have investigated hypothermia for TBI, finding no clear evidence of improved outcomes with hypothermia compared to normothermia. The document concludes by discussing reasons for the lack of evidence and considerations for future trials, as the role of hypothermia in TBI remains uncertain.
1) The study used high-resolution MRI to measure the dimensions of the cavernous sinus and surrounding structures in patients with cluster headache, chronic paroxysmal hemicrania, and controls.
2) They found that patients with cluster headache and chronic paroxysmal hemicrania had wider skulls than controls. However, after adjusting for skull size, there were no differences in the dimensions of the cavernous sinus between patients and controls.
3) One finding was that probable cluster headache patients had a larger left-to-right pituitary diameter compared to controls, but pituitary volumes did not differ between groups. Overall, the study found no evidence that cavernous sinus dimensions are constitutionally narrow
Intraoperative Monitoring for Brain and Spinal Cord TumorsDhaval Shukla
Intraoperative monitoring (IOM) during brain and spinal surgeries aims to prevent new or worsened neurological deficits. While IOM is not based on class I evidence, controlled studies would be unethical given its effectiveness in predicting injuries. Studies show IOM reduces postoperative deficits compared to no monitoring. For glioma resections, IOM-guided resection allows safer maximal removal in eloquent areas, improving survival and quality of life. Awake craniotomy with IOM results in fewer deficits than general anesthesia. While false negatives and cost are challenges, IOM avoidance risks greater deficits and rehabilitation costs. IOM should be used for brain and spinal tumor resections when near critical structures.
1) Hypothermia has been proposed as a treatment for traumatic brain injury (TBI) to help reduce secondary brain damage.
2) Previous studies on hypothermia for TBI have shown mixed results, with some trials finding benefits and others finding no effect.
3) The author conducted a randomized controlled trial of 107 patients with severe TBI to study the effects of progesterone, hypothermia, or their combination on outcomes.
4) The trial found the best outcomes based on Glasgow Outcome Scale at 6 months in the hypothermia group, followed by the progesterone group, though the combination did not provide additional benefit over hypothermia alone.
1) Hypothermia has been proposed as a treatment for traumatic brain injury (TBI) to help reduce secondary brain damage.
2) Previous studies on hypothermia for TBI have shown mixed results, with some trials finding benefits and others finding no effect.
3) The author conducted a randomized controlled trial of 107 patients with severe TBI to study the effects of progesterone, hypothermia, or their combination on outcomes.
4) The trial found the best outcomes based on Glasgow Outcome Scale at 6 months in the hypothermia group, followed by the progesterone group, though the combination did not provide additional benefit over hypothermia alone.
Management of High Disease Activity in Multiple Sclerosis (MS)Sudhir Kumar
Multiple sclerosis is a common disease affecting the central nervous system. Immunotherapy with interferon is the first line therapy for MS. This presentation discusses the treatment options of high disease activity in patients with MS. Role of natalizumab (tysabri) has been highlighted.
Subarachnoid hemorrhage (SAH) is a serious condition with high mortality and morbidity. Survivors often have reduced quality of life and dependence. Outcomes are influenced by clinical factors like age, hypertension, and severity of bleed, as well as availability of specialized care and rehabilitation. Rehabilitation should begin as soon as medically feasible and involve a multidisciplinary team addressing physical, cognitive, and psychosocial impairments. With comprehensive rehabilitation, outcomes after SAH can improve over time.
This document summarizes a journal club discussion of a randomized trial comparing outcomes of intracranial pressure monitoring versus clinical examination alone for patients with severe traumatic brain injury. Key points included that the trial found similar outcomes between the two groups in composite endpoints and mortality. However, the intracranial pressure monitoring group received more aggressive treatments such as barbiturates. There was skepticism around applying the results to clinical practice in the US due to differences in pre-hospital care, rehabilitation standards, and treatment protocols between the study locations and the US.
Responsive Neurostimulation (RNS) for Intractable EpilepsyAllina Health
The RNS system is an FDA-approved treatment for drug-resistant epilepsy that involves surgically implanting a neurostimulator device to detect and respond to seizure activity. Clinical trials found that the RNS system provided a median seizure reduction of over 37% within 3 months for treated patients compared to a 25.2% reduction for the sham group. Long-term follow-up over 7 years found the RNS system maintained seizure control effectiveness and was safe, with no chronic neurological effects reported. The RNS system may be an option for patients who have failed two or more anti-seizure medications and are not candidates for resective epilepsy surgery.
This document presents a systematic review and meta-analyses of neuroprotective agents used for traumatic brain injury. It summarizes 18 randomized controlled trials evaluating the efficacy of various agents, including erythropoietin, citicoline, progesterone, oxygen, corticosteroids, monoaminergic agents, magnesium, cerebrolysin, and cyclosporine A. The primary objectives were to determine what new evidence exists since prior reviews in 2015 and evaluate the agents' effects on outcomes like mortality, functional recovery, and side effects. Most agents showed limited or no evidence of benefit, though erythropoietin, progesterone, and oxygen demonstrated some promising results requiring further large randomized trials.
“8th National Biennial Conference on Medical Informatics 2012” Ashu Ash
This document discusses using eLearning to reduce costs and improve adoption of electronic medical record (EMR) systems during implementation in hospitals. Traditional classroom training for thousands of staff was very expensive and time consuming. The approach taken was to develop an enterprise training portal with online courses tailored for different roles. This allowed asynchronous learning over several weeks. Classroom time was reduced to introduce the portal. Costs were cut by 75% and training was completed in two months, achieving a critical mass of adoption, compared to over 10 months for traditional training. eLearning improved the scalability and affordability of training for successful EMR implementation.
The Neuroprotective Effects of Ketones in TBIBryan Barksdale
Traumatic Brain Injury (TBI) is the number one cause of death and chronic disability for those under the age of 45. Unfortunately there are few current treatments available and there has been a large failure to translate neuroprotective treatments from animal models. One potential reason is that metabolic dysfunction, a key part of TBI pathophysiology is not addressed. Ketogenic diets and exogenous ketones have been shown to have neuroprotective effects through multiple mechanisms in animal models of TBI, including the reversal of metabolic dysfunction. I will discuss the current evidence for the KD in the treatment of TBI. I will also briefly discuss other nutritional and lifestyle factors in the treatment of TBI.
Presentation during IFNR 2016.
Brief description with available evidence on various coma arousal therapy with an illustrative study for each therapy and recommendation for future.
IRJET- Portable Supporting Device for Narcoleptic PatientsIRJET Journal
This document describes a portable supporting device for patients with narcolepsy. The device uses an EEG sensor to constantly monitor brain waves and detect the onset of narcoleptic sleep. When sleep onset is detected, the device prevents sleep by providing external disturbances through vibration motors, alerting the patient. A study showed the EEG technique could accurately detect sleep onset 87.5% of the time compared to polysomnography. The portable device allows independent monitoring of narcoleptic patients to prevent dangers from unexpected sleep episodes.
Long-term cognitive impairment after critical illness (CIACI) is frequently reported in up to 66% of patients three months after intensive care hospitalization. The condition has overlapping neurological changes with stroke, traumatic brain injury, and neurodegenerative disorders. Risk factors for CIACI include depression, biomarkers for Alzheimer's disease, delirium duration during hospitalization, and exposure to certain drugs. Current strategies to prevent or treat CIACI focus on reducing delirium and agitation, as well as physical and cognitive rehabilitation. Neurotrophic factors may play a role in neurogenesis, blood-brain barrier integrity, and neuronal repair, suggesting they could be a potential target for novel CIACI treatments.
This study evaluated the efficacy and safety of long-term intravenous immunoglobulin (IVIg) treatment for 52 weeks in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). 49 patients received IVIg 1g/kg every 3 weeks for 52 weeks. The primary outcomes were a responder rate of 1 point improvement on the INCAT score at 28 weeks and relapse rate at 52 weeks. At 28 weeks, 77.6% of patients responded, higher than previous studies. The clinical remission rate was maintained at 69.4% at 52 weeks. Secondary outcomes also improved. Adverse events included cerebral infarction in 2 older patients. The study demonstrated efficacy of 52-week IVI
This document summarizes various interventional treatments for headaches including occipital nerve blocks, pulsed radiofrequency of the occipital nerve, and occipital nerve stimulation. It provides epidemiological data on migraine and cluster headaches. It also discusses indications for occipital nerve blocks including various headache types. Peripheral nerve blocks are described as commonly used but with variable methodology. Effectiveness of occipital nerve stimulation is supported for various intractable headache conditions but lead migration is a technical challenge.
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) is a rare neurological disorder characterized by progressive weakness and impaired sensory function caused by damage to the peripheral nervous system. It has an incidence rate of 1-2 per 100,000 people and predominantly affects males over 50 years old. CIDP is diagnosed based on progressive muscle weakness, reduced reflexes, nerve conduction studies showing demyelination, elevated CSF protein, and nerve biopsy with signs of demyelination. Treatment involves intravenous immunoglobulin, plasma exchange, steroids, or other immunosuppressants, with around 50% of patients experiencing improvement with therapy.
Vns Therapy™ System For Weikong For Printcalaf0618
The document discusses VNS Therapy, a treatment for epilepsy patients who have difficulty controlling seizures through medications alone. It provides information on:
- How VNS Therapy works by electrically stimulating the vagus nerve to impact brain regions involved in seizure activity.
- Clinical evidence that VNS Therapy can significantly reduce seizure frequency in refractory epilepsy patients and improve quality of life factors like mood and alertness.
- Safety data showing the risks of VNS Therapy are low, with most side effects being mild and transient.
- High patient and clinician satisfaction rates with VNS Therapy as an effective alternative or addition to medications for difficult-to-treat epilepsy.
This document presents a systematic review and meta-analysis of neuroprotective agents used for traumatic brain injury. It describes traumatic brain injury and various neuroprotective interventions that have been studied, including oxygen, corticosteroids, progesterone, monoaminergic agents, erythropoietin, magnesium, cerebrolysin, and citicoline. For each intervention, the document summarizes the relevant randomized controlled trials, findings on outcomes like mortality, and recommendations for further research. The overall goal is to evaluate the evidence on various neuroprotective agents and identify priorities for future clinical trials.
Martin Smith
The management of severe traumatic brain injury (TBI) has undergone extensive revision following evidence that longstanding and established practices are not as efficacious or innocuous as previously believed. Very few specific interventions have been shown to improve outcome in large randomized controlled trials and, with the possible exception of avoidance of hypotension and hypoxaemia, most are based on observational studies or analysis of physiology and pathophysiology. Further, the substantial temporal and regional pathophysiological heterogeneity after TBI means that some interventions may be ineffective, unnecessary or even harmful in certain patients at certain times.
Improved understanding of pathophysiology and advances in neuromonitoring and imaging techniques have led to the introduction of more effective and individualised treatment strategies that have translated into improved outcomes for patients. In particular, the sole goal of identifying and treating intracranial hypertension has been superseded by a focus on the prevention of secondary brain insults using a systematic, stepwise approach to maintenance of adequate cerebral perfusion and oxygenation. As well as being used to guide treatment interventions, multimodal neuromonitoring also gives clinicians confidence to withhold potentially dangerous therapy in those with no evidence of brain ischemia/hypoxia or metabolic disturbance.
The days of blind adherence to generic physiological targets in the management of severe TBI have been replaced by an individualised approach to optimisation of physiology which has translated into improved outcomes for patients.
Mark Wilson
The New England Journal of Medicine has published a number of articles recently that demonstrate no benefit from classic neurotrauma interventions (ICP monitoring, cooling, decompression). This is because factors such as ICP and CPP are associated with bad outcome by association rather than causation. This debate will demonstrate that critical care just complicates things and it is high time for the randomised trial between the very best Neurocritical care and NOB therapy (Naso-pharyngeal, Oxygen and a Blanket).
Switching therapy in Multiple sclerosisDivya Shilpa
1) A 37-year-old housewife, Mrs. S.D., has relapsing-remitting multiple sclerosis. She has experienced breakthrough disease activity while on interferon beta therapy.
2) The document discusses criteria for evaluating clinically relevant disease activity and considerations for treatment adjustment, including relapse rate, disability progression, and MRI findings. It also reviews options for switching or adding therapy, such as increasing interferon beta dose or switching to glatiramer acetate, natalizumab, fingolimod, or other drugs.
3) The evidence on switching therapies suggests that some patients with suboptimal response to interferon beta may experience reduced relapse rates and disability progression after switching to glat
Transcranial magnetic stimulation (TMS) is a non-invasive treatment for major depressive disorder that uses magnetic pulses to stimulate nerve cells in the brain. A review of the efficacy of TMS found that it is an effective alternative or addition to treatments like antidepressants and psychotherapy. TMS works by inducing electric currents in the brain via electromagnetic induction to modulate neuronal activity. It has shown response rates of about 60% in clinical trials with mostly mild side effects like brief scalp discomfort. TMS may help reduce the burden of depression, which is high in India, by providing an additional treatment option.
Debate: Neurocritical Care Improves Outcomes in Severe TBISMACC Conference
Martin Smith and Mark Wilson debate whether neurocritical care improves outcomes in severe TBI.
Martin argues in favour of neurocritical care.
He concedes that longstanding and established practices are not as efficacious or innocuous as previously believed.
Very few specific interventions have been shown to improve outcomes in large randomised controlled trials. With the possible exception of avoidance of hypotension and hypoxaemia, most are based on analysis of physiology and pathophysiology.
Further, the substantial temporal and regional pathophysiological heterogeneity after TBI means that some interventions may be ineffective, unnecessary, or even harmful in certain patients at certain times.
Martin however, contends that improved understanding of pathophysiology and advances in neuromonitoring and imaging techniques have led to more effective and individualised treatment strategies. Ultimately, this has led to improved outcomes for patients.
In particular, the sole goal of identifying and treating intracranial hypertension has been superseded by a focus on the prevention of secondary brain insults. This is done by using a systematic, stepwise approach to maintenance of adequate cerebral perfusion and oxygenation.
Similarly, multimodal neuromonitoring also gives clinicians confidence to withhold potentially dangerous therapy. Particuarly in those with no evidence of brain ischemia/hypoxia or metabolic disturbance.
Mark Wilson on the other hand argues there is no benefit in neurocritical care following severe TBI.
The New England Journal of Medicine has published several articles that demonstrate no benefit from classic neurotrauma interventions (ICP monitoring, cooling, decompression). This is because factors such as ICP and CPP associate with bad outcomes by association rather than causation.
This debate will demonstrate that critical care just complicates things. Evidently, it is high time for the randomised trial between the very best neurocritical care and NOB therapy (Naso-pharyngeal, Oxygen and a Blanket).
Join Martin and Mark as they discuss the pros and cons of neurocritical care in the management of severe TBI.
For more like this, head to our podcast page. #CodaPodcast
This document discusses anesthesia and surgery risks in older patients. It defines postoperative cognitive dysfunction (POCD) and reviews risk factors. Neuroinflammation from surgery and anesthesia may cause POCD through breakdown of the blood-brain barrier and neurotoxic effects. Risk factors for POCD include age, preexisting cognitive impairment, diabetes, hypertension and sleep disorders. A comprehensive geriatric assessment evaluates medical, functional and social risks. Prevention prioritizes optimization of risk factors through treatment of medical conditions and good perioperative care. Most POCD cases resolve within months without direct treatment.
Management of High Disease Activity in Multiple Sclerosis (MS)Sudhir Kumar
Multiple sclerosis is a common disease affecting the central nervous system. Immunotherapy with interferon is the first line therapy for MS. This presentation discusses the treatment options of high disease activity in patients with MS. Role of natalizumab (tysabri) has been highlighted.
Subarachnoid hemorrhage (SAH) is a serious condition with high mortality and morbidity. Survivors often have reduced quality of life and dependence. Outcomes are influenced by clinical factors like age, hypertension, and severity of bleed, as well as availability of specialized care and rehabilitation. Rehabilitation should begin as soon as medically feasible and involve a multidisciplinary team addressing physical, cognitive, and psychosocial impairments. With comprehensive rehabilitation, outcomes after SAH can improve over time.
This document summarizes a journal club discussion of a randomized trial comparing outcomes of intracranial pressure monitoring versus clinical examination alone for patients with severe traumatic brain injury. Key points included that the trial found similar outcomes between the two groups in composite endpoints and mortality. However, the intracranial pressure monitoring group received more aggressive treatments such as barbiturates. There was skepticism around applying the results to clinical practice in the US due to differences in pre-hospital care, rehabilitation standards, and treatment protocols between the study locations and the US.
Responsive Neurostimulation (RNS) for Intractable EpilepsyAllina Health
The RNS system is an FDA-approved treatment for drug-resistant epilepsy that involves surgically implanting a neurostimulator device to detect and respond to seizure activity. Clinical trials found that the RNS system provided a median seizure reduction of over 37% within 3 months for treated patients compared to a 25.2% reduction for the sham group. Long-term follow-up over 7 years found the RNS system maintained seizure control effectiveness and was safe, with no chronic neurological effects reported. The RNS system may be an option for patients who have failed two or more anti-seizure medications and are not candidates for resective epilepsy surgery.
This document presents a systematic review and meta-analyses of neuroprotective agents used for traumatic brain injury. It summarizes 18 randomized controlled trials evaluating the efficacy of various agents, including erythropoietin, citicoline, progesterone, oxygen, corticosteroids, monoaminergic agents, magnesium, cerebrolysin, and cyclosporine A. The primary objectives were to determine what new evidence exists since prior reviews in 2015 and evaluate the agents' effects on outcomes like mortality, functional recovery, and side effects. Most agents showed limited or no evidence of benefit, though erythropoietin, progesterone, and oxygen demonstrated some promising results requiring further large randomized trials.
“8th National Biennial Conference on Medical Informatics 2012” Ashu Ash
This document discusses using eLearning to reduce costs and improve adoption of electronic medical record (EMR) systems during implementation in hospitals. Traditional classroom training for thousands of staff was very expensive and time consuming. The approach taken was to develop an enterprise training portal with online courses tailored for different roles. This allowed asynchronous learning over several weeks. Classroom time was reduced to introduce the portal. Costs were cut by 75% and training was completed in two months, achieving a critical mass of adoption, compared to over 10 months for traditional training. eLearning improved the scalability and affordability of training for successful EMR implementation.
The Neuroprotective Effects of Ketones in TBIBryan Barksdale
Traumatic Brain Injury (TBI) is the number one cause of death and chronic disability for those under the age of 45. Unfortunately there are few current treatments available and there has been a large failure to translate neuroprotective treatments from animal models. One potential reason is that metabolic dysfunction, a key part of TBI pathophysiology is not addressed. Ketogenic diets and exogenous ketones have been shown to have neuroprotective effects through multiple mechanisms in animal models of TBI, including the reversal of metabolic dysfunction. I will discuss the current evidence for the KD in the treatment of TBI. I will also briefly discuss other nutritional and lifestyle factors in the treatment of TBI.
Presentation during IFNR 2016.
Brief description with available evidence on various coma arousal therapy with an illustrative study for each therapy and recommendation for future.
IRJET- Portable Supporting Device for Narcoleptic PatientsIRJET Journal
This document describes a portable supporting device for patients with narcolepsy. The device uses an EEG sensor to constantly monitor brain waves and detect the onset of narcoleptic sleep. When sleep onset is detected, the device prevents sleep by providing external disturbances through vibration motors, alerting the patient. A study showed the EEG technique could accurately detect sleep onset 87.5% of the time compared to polysomnography. The portable device allows independent monitoring of narcoleptic patients to prevent dangers from unexpected sleep episodes.
Long-term cognitive impairment after critical illness (CIACI) is frequently reported in up to 66% of patients three months after intensive care hospitalization. The condition has overlapping neurological changes with stroke, traumatic brain injury, and neurodegenerative disorders. Risk factors for CIACI include depression, biomarkers for Alzheimer's disease, delirium duration during hospitalization, and exposure to certain drugs. Current strategies to prevent or treat CIACI focus on reducing delirium and agitation, as well as physical and cognitive rehabilitation. Neurotrophic factors may play a role in neurogenesis, blood-brain barrier integrity, and neuronal repair, suggesting they could be a potential target for novel CIACI treatments.
This study evaluated the efficacy and safety of long-term intravenous immunoglobulin (IVIg) treatment for 52 weeks in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). 49 patients received IVIg 1g/kg every 3 weeks for 52 weeks. The primary outcomes were a responder rate of 1 point improvement on the INCAT score at 28 weeks and relapse rate at 52 weeks. At 28 weeks, 77.6% of patients responded, higher than previous studies. The clinical remission rate was maintained at 69.4% at 52 weeks. Secondary outcomes also improved. Adverse events included cerebral infarction in 2 older patients. The study demonstrated efficacy of 52-week IVI
This document summarizes various interventional treatments for headaches including occipital nerve blocks, pulsed radiofrequency of the occipital nerve, and occipital nerve stimulation. It provides epidemiological data on migraine and cluster headaches. It also discusses indications for occipital nerve blocks including various headache types. Peripheral nerve blocks are described as commonly used but with variable methodology. Effectiveness of occipital nerve stimulation is supported for various intractable headache conditions but lead migration is a technical challenge.
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) is a rare neurological disorder characterized by progressive weakness and impaired sensory function caused by damage to the peripheral nervous system. It has an incidence rate of 1-2 per 100,000 people and predominantly affects males over 50 years old. CIDP is diagnosed based on progressive muscle weakness, reduced reflexes, nerve conduction studies showing demyelination, elevated CSF protein, and nerve biopsy with signs of demyelination. Treatment involves intravenous immunoglobulin, plasma exchange, steroids, or other immunosuppressants, with around 50% of patients experiencing improvement with therapy.
Vns Therapy™ System For Weikong For Printcalaf0618
The document discusses VNS Therapy, a treatment for epilepsy patients who have difficulty controlling seizures through medications alone. It provides information on:
- How VNS Therapy works by electrically stimulating the vagus nerve to impact brain regions involved in seizure activity.
- Clinical evidence that VNS Therapy can significantly reduce seizure frequency in refractory epilepsy patients and improve quality of life factors like mood and alertness.
- Safety data showing the risks of VNS Therapy are low, with most side effects being mild and transient.
- High patient and clinician satisfaction rates with VNS Therapy as an effective alternative or addition to medications for difficult-to-treat epilepsy.
This document presents a systematic review and meta-analysis of neuroprotective agents used for traumatic brain injury. It describes traumatic brain injury and various neuroprotective interventions that have been studied, including oxygen, corticosteroids, progesterone, monoaminergic agents, erythropoietin, magnesium, cerebrolysin, and citicoline. For each intervention, the document summarizes the relevant randomized controlled trials, findings on outcomes like mortality, and recommendations for further research. The overall goal is to evaluate the evidence on various neuroprotective agents and identify priorities for future clinical trials.
Martin Smith
The management of severe traumatic brain injury (TBI) has undergone extensive revision following evidence that longstanding and established practices are not as efficacious or innocuous as previously believed. Very few specific interventions have been shown to improve outcome in large randomized controlled trials and, with the possible exception of avoidance of hypotension and hypoxaemia, most are based on observational studies or analysis of physiology and pathophysiology. Further, the substantial temporal and regional pathophysiological heterogeneity after TBI means that some interventions may be ineffective, unnecessary or even harmful in certain patients at certain times.
Improved understanding of pathophysiology and advances in neuromonitoring and imaging techniques have led to the introduction of more effective and individualised treatment strategies that have translated into improved outcomes for patients. In particular, the sole goal of identifying and treating intracranial hypertension has been superseded by a focus on the prevention of secondary brain insults using a systematic, stepwise approach to maintenance of adequate cerebral perfusion and oxygenation. As well as being used to guide treatment interventions, multimodal neuromonitoring also gives clinicians confidence to withhold potentially dangerous therapy in those with no evidence of brain ischemia/hypoxia or metabolic disturbance.
The days of blind adherence to generic physiological targets in the management of severe TBI have been replaced by an individualised approach to optimisation of physiology which has translated into improved outcomes for patients.
Mark Wilson
The New England Journal of Medicine has published a number of articles recently that demonstrate no benefit from classic neurotrauma interventions (ICP monitoring, cooling, decompression). This is because factors such as ICP and CPP are associated with bad outcome by association rather than causation. This debate will demonstrate that critical care just complicates things and it is high time for the randomised trial between the very best Neurocritical care and NOB therapy (Naso-pharyngeal, Oxygen and a Blanket).
Switching therapy in Multiple sclerosisDivya Shilpa
1) A 37-year-old housewife, Mrs. S.D., has relapsing-remitting multiple sclerosis. She has experienced breakthrough disease activity while on interferon beta therapy.
2) The document discusses criteria for evaluating clinically relevant disease activity and considerations for treatment adjustment, including relapse rate, disability progression, and MRI findings. It also reviews options for switching or adding therapy, such as increasing interferon beta dose or switching to glatiramer acetate, natalizumab, fingolimod, or other drugs.
3) The evidence on switching therapies suggests that some patients with suboptimal response to interferon beta may experience reduced relapse rates and disability progression after switching to glat
Transcranial magnetic stimulation (TMS) is a non-invasive treatment for major depressive disorder that uses magnetic pulses to stimulate nerve cells in the brain. A review of the efficacy of TMS found that it is an effective alternative or addition to treatments like antidepressants and psychotherapy. TMS works by inducing electric currents in the brain via electromagnetic induction to modulate neuronal activity. It has shown response rates of about 60% in clinical trials with mostly mild side effects like brief scalp discomfort. TMS may help reduce the burden of depression, which is high in India, by providing an additional treatment option.
Debate: Neurocritical Care Improves Outcomes in Severe TBISMACC Conference
Martin Smith and Mark Wilson debate whether neurocritical care improves outcomes in severe TBI.
Martin argues in favour of neurocritical care.
He concedes that longstanding and established practices are not as efficacious or innocuous as previously believed.
Very few specific interventions have been shown to improve outcomes in large randomised controlled trials. With the possible exception of avoidance of hypotension and hypoxaemia, most are based on analysis of physiology and pathophysiology.
Further, the substantial temporal and regional pathophysiological heterogeneity after TBI means that some interventions may be ineffective, unnecessary, or even harmful in certain patients at certain times.
Martin however, contends that improved understanding of pathophysiology and advances in neuromonitoring and imaging techniques have led to more effective and individualised treatment strategies. Ultimately, this has led to improved outcomes for patients.
In particular, the sole goal of identifying and treating intracranial hypertension has been superseded by a focus on the prevention of secondary brain insults. This is done by using a systematic, stepwise approach to maintenance of adequate cerebral perfusion and oxygenation.
Similarly, multimodal neuromonitoring also gives clinicians confidence to withhold potentially dangerous therapy. Particuarly in those with no evidence of brain ischemia/hypoxia or metabolic disturbance.
Mark Wilson on the other hand argues there is no benefit in neurocritical care following severe TBI.
The New England Journal of Medicine has published several articles that demonstrate no benefit from classic neurotrauma interventions (ICP monitoring, cooling, decompression). This is because factors such as ICP and CPP associate with bad outcomes by association rather than causation.
This debate will demonstrate that critical care just complicates things. Evidently, it is high time for the randomised trial between the very best neurocritical care and NOB therapy (Naso-pharyngeal, Oxygen and a Blanket).
Join Martin and Mark as they discuss the pros and cons of neurocritical care in the management of severe TBI.
For more like this, head to our podcast page. #CodaPodcast
This document discusses anesthesia and surgery risks in older patients. It defines postoperative cognitive dysfunction (POCD) and reviews risk factors. Neuroinflammation from surgery and anesthesia may cause POCD through breakdown of the blood-brain barrier and neurotoxic effects. Risk factors for POCD include age, preexisting cognitive impairment, diabetes, hypertension and sleep disorders. A comprehensive geriatric assessment evaluates medical, functional and social risks. Prevention prioritizes optimization of risk factors through treatment of medical conditions and good perioperative care. Most POCD cases resolve within months without direct treatment.
Therapeutic hypothermia has been suggested as a treatment for severe traumatic brain injury (TBI) to reduce secondary brain injury. It can be used prophylactically in the early phases after injury or to control elevated intracranial pressure in the intermediate phase. While prophylactic hypothermia's efficacy is still unclear from conflicting studies, hypothermia for refractory intracranial hypertension has shown promise in reducing pressure and improving outcomes based on clinical trials. Optimal temperatures, duration, and rewarming rates need further study to maximize benefits and minimize complications of this therapeutic approach for TBI.
pain management after craniotomy and spine surgery. as a neuroanesthesiologist it our duty to manage post operative pain. pain in these patient are under treated.
The document discusses approaches to promoting regeneration after spinal cord injury. It describes how secondary injury mechanisms can cause additional damage after the initial injury. Research strategies aim to minimize secondary damage, promote axon regeneration through the injury site, and exploit intact fibers. Potential treatments include neuroprotection, stimulating axon growth by blocking myelin inhibitors, bridging the injury site with cellular grafts, and rehabilitation. Large clinical trials are needed to evaluate safety and efficacy.
Lessons from the TTM trial and planning for the nexstscanFOAM
1) Detailed neurological examinations and blinded prognostication were conducted in the TTM trials to minimize bias in outcomes.
2) Follow-up assessments at 6 months in TTM1 found cognitive impairment, depression, and reduced quality of life in about one third of patients despite similar mortality between groups.
3) Extended cognitive testing in TTM1 at 6 months revealed memory, executive function, and processing speed impairments in about half of patients, more than in risk-factor matched controls, showing long-term cognitive consequences after cardiac arrest.
This document discusses the role of neurointensivists in neurosurgical care and training. It describes neurocritical care as a subspecialty focused on comprehensive care of critically ill neurological patients. It reviews the requirements for board certification in neurocritical care, which was first offered in 2007. It also discusses how neurointensivists can be involved in neurosurgical residency training, such as collaborating on didactic sessions and ensuring adequate intensive care unit exposure for residents.
Annovis Bio is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to be the only company developing a drug for AD, PD and AD-DS that inhibits
more than one neurotoxic protein and improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. The company expects its treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. Annovis has an ongoing
Phase 2a study in AD patients and a second Phase 2a study in early PD and early AD patients.
The document summarizes guidelines from the Brain Trauma Foundation (BTF) for the management of severe traumatic brain injury (TBI). The BTF released the 4th edition of these guidelines in 2016 to provide evidence-based recommendations for treating severe TBIs. The guidelines provide recommendations on various treatment strategies, such as decompressive craniectomy, hypothermia, hyperosmolar therapy, cerebrospinal fluid drainage, ventilation, anesthetics/sedatives, and monitoring thresholds. Each recommendation is assigned a level depending on the quality of evidence.
Annovis Bio is a clinical-stage, drug platform company addressing
neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease
(PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to
be the only company developing a drug for AD, PD and AD-DS that inhibits
more than one neurotoxic protein and improves the information highway of
the nerve cell, known as axonal transport. When this information flow is
impaired, the nerve cell gets sick and dies. The company expects its
treatment to improve memory loss and dementia associated with AD and
AD-DS, as well as body and brain function in PD. Annovis has an ongoing
Phase 2a study in AD patients and a second Phase 2a study in early PD
and early AD patients.
The document summarizes recent discoveries in spinal cord injury pathophysiology and treatment from The Miami Project to Cure Paralysis. It discusses promising neuroprotective and regenerative treatments currently being studied, including hypothermia, stem cells, and Schwann cell transplantation. It also outlines ongoing clinical trials, such as the ARCTIC trial evaluating hypothermia and a proposed phase 1 trial of autologous Schwann cell transplantation in humans with spinal cord injuries. The overall goal is to translate bench research into new clinical applications and improve outcomes for spinal cord injury patients.
This document discusses an alternative model for a neurocritical care unit (NCCU) called a "Global NCCU". A Global NCCU provides care for neurologically impaired patients across multiple units of the hospital rather than focusing only on patients in a dedicated NCCU. The document outlines the key components of a NCCU, compares specialty and global models, and describes the steps taken at St. Jude Medical Center to develop a successful Global NCCU model including establishing neurointensivists, dedicated neuro nurses, standardized processes, education, and administrative support.
1. Transcranial Doppler ultrasound (TCD) can be used as a non-invasive method to monitor patients with traumatic brain injury (TBI). TCD allows clinicians to detect posttraumatic vasospasm and increased intracranial pressure, which are major contributors to secondary brain injury in moderate and severe TBI patients.
2. TCD is highly sensitive for detecting abnormally high cerebral blood flow velocities caused by vasospasm and can help guide treatment decisions. Daily TCD monitoring is recommended for managing TBI patients at risk of vasospasm and increased intracranial pressure.
3. TCD can also assess cerebrovascular reactivity as an indicator of brain regulation following TBI
This document discusses evidence supporting the use of the ABCDEF bundle and Society of Critical Care Medicine's (SCCM) guidelines for managing pain, agitation, and delirium (PAD) in mechanically ventilated patients. It summarizes the 2013 SCCM PAD guidelines, which establish an overarching approach to daily patient management focusing on assessing and treating pain first, avoiding deep sedation and benzodiazepines, screening for delirium, and using the ABCDEF bundle to improve outcomes. Studies found implementing more than six strategies along with the PAD guidelines or ABCDE bundle reduced mortality and ICU length of stay, while incomplete implementation yielded lower success rates.
as the life expectancy has increased. more and more elderly patients are undergoing surgery. the burden of postoperative dysfunction has to be increased in future. There should be attempt to identify the risk factors and measures to prevent POCD.
This document provides guidelines for the management of severe traumatic brain injury. It discusses various treatments and recommendations based on evidence levels. For decompressive craniectomy, the guidelines recommend a large frontotemporoparietal craniectomy over a small one to control intracranial pressure. For hypothermia and steroids, the guidelines do not recommend their use to improve outcomes. Infection prevention strategies like early tracheostomy are suggested to reduce ventilation time, but povidone-iodine oral care is not advised due to risks.
Similar to Victoria McCredie minimizing secondary injury #ISICEM19 #IFAD2019 (20)
A neglected topic for way too long, the interest in fluid therapy seems to be quickly rising as the medical community is making a shift from looking at fluids as a mere method of stabilization towards the appreciation of its relevant side effects.
Many questions remain to be answered indeed:
Is the upgrade from saline 0.9% to balanced crystalloids worth the extra cost?
Does HES still have a place in the OR?
Do we have to fill the gap left by HES on ICU with crystalloids, other colloids or even albumin?
Is it really impossible to avoid fluid overload by using only crystalloids?
Is there still a definitive place for human albumin?
How do we treat and monitor specific patient populations, like patients with trauma, liver failure, brain edema and right heart failure among others?
How do we avoid a one-size-fits-all regimen in perioperative goal-directed therapy?
What with the fluids beyond resuscitation?
And what do the authors of the big fluid trials do in real life themselves?
The 9th International Fluid Academy Day will again be a 1 day concise meeting on all aspects of fluid managament and hemodynamic monitoring in the critically ill.
Date: October 26th 2019, 8:00 - 18:00
A neglected topic for way too long, the interest in fluid therapy seems to be quickly rising as the medical community is making a shift from looking at fluids as a mere method of stabilization towards the appreciation of its relevant side effects.
Many questions remain to be answered indeed:
Is the upgrade from saline 0.9% to balanced crystalloids worth the extra cost?
Does HES still have a place in the OR?
Do we have to fill the gap left by HES on ICU with crystalloids, other colloids or even albumin?
Is it really impossible to avoid fluid overload by using only crystalloids?
Is there still a definitive place for human albumin?
How do we treat and monitor specific patient populations, like patients with trauma, liver failure, brain edema and right heart failure among others?
How do we avoid a one-size-fits-all regimen in perioperative goal-directed therapy?
What with the fluids beyond resuscitation?
And what do the authors of the big fluid trials do in real life themselves?
The 9th International Fluid Academy Day will again be a 1 day concise meeting on all aspects of fluid managament and hemodynamic monitoring in the critically ill.
Date: October 26th 2019, 8:00 - 18:00
A neglected topic for way too long, the interest in fluid therapy seems to be quickly rising as the medical community is making a shift from looking at fluids as a mere method of stabilization towards the appreciation of its relevant side effects.
Many questions remain to be answered indeed:
Is the upgrade from saline 0.9% to balanced crystalloids worth the extra cost?
Does HES still have a place in the OR?
Do we have to fill the gap left by HES on ICU with crystalloids, other colloids or even albumin?
Is it really impossible to avoid fluid overload by using only crystalloids?
Is there still a definitive place for human albumin?
How do we treat and monitor specific patient populations, like patients with trauma, liver failure, brain edema and right heart failure among others?
How do we avoid a one-size-fits-all regimen in perioperative goal-directed therapy?
What with the fluids beyond resuscitation?
And what do the authors of the big fluid trials do in real life themselves?
The 9th International Fluid Academy Day will again be a 1 day concise meeting on all aspects of fluid managament and hemodynamic monitoring in the critically ill.
Date: October 26th 2019, 8:00 - 18:00
A neglected topic for way too long, the interest in fluid therapy seems to be quickly rising as the medical community is making a shift from looking at fluids as a mere method of stabilization towards the appreciation of its relevant side effects.
Many questions remain to be answered indeed:
Is the upgrade from saline 0.9% to balanced crystalloids worth the extra cost?
Does HES still have a place in the OR?
Do we have to fill the gap left by HES on ICU with crystalloids, other colloids or even albumin?
Is it really impossible to avoid fluid overload by using only crystalloids?
Is there still a definitive place for human albumin?
How do we treat and monitor specific patient populations, like patients with trauma, liver failure, brain edema and right heart failure among others?
How do we avoid a one-size-fits-all regimen in perioperative goal-directed therapy?
What with the fluids beyond resuscitation?
And what do the authors of the big fluid trials do in real life themselves?
The 9th International Fluid Academy Day will again be a 1 day concise meeting on all aspects of fluid managament and hemodynamic monitoring in the critically ill.
Date: October 26th 2019, 8:00 - 18:00
A neglected topic for way too long, the interest in fluid therapy seems to be quickly rising as the medical community is making a shift from looking at fluids as a mere method of stabilization towards the appreciation of its relevant side effects.
Many questions remain to be answered indeed:
Is the upgrade from saline 0.9% to balanced crystalloids worth the extra cost?
Does HES still have a place in the OR?
Do we have to fill the gap left by HES on ICU with crystalloids, other colloids or even albumin?
Is it really impossible to avoid fluid overload by using only crystalloids?
Is there still a definitive place for human albumin?
How do we treat and monitor specific patient populations, like patients with trauma, liver failure, brain edema and right heart failure among others?
How do we avoid a one-size-fits-all regimen in perioperative goal-directed therapy?
What with the fluids beyond resuscitation?
And what do the authors of the big fluid trials do in real life themselves?
The 9th International Fluid Academy Day will again be a 1 day concise meeting on all aspects of fluid managament and hemodynamic monitoring in the critically ill.
Date: October 26th 2019, 8:00 - 18:00
A neglected topic for way too long, the interest in fluid therapy seems to be quickly rising as the medical community is making a shift from looking at fluids as a mere method of stabilization towards the appreciation of its relevant side effects.
Many questions remain to be answered indeed:
Is the upgrade from saline 0.9% to balanced crystalloids worth the extra cost?
Does HES still have a place in the OR?
Do we have to fill the gap left by HES on ICU with crystalloids, other colloids or even albumin?
Is it really impossible to avoid fluid overload by using only crystalloids?
Is there still a definitive place for human albumin?
How do we treat and monitor specific patient populations, like patients with trauma, liver failure, brain edema and right heart failure among others?
How do we avoid a one-size-fits-all regimen in perioperative goal-directed therapy?
What with the fluids beyond resuscitation?
And what do the authors of the big fluid trials do in real life themselves?
The 9th International Fluid Academy Day will again be a 1 day concise meeting on all aspects of fluid managament and hemodynamic monitoring in the critically ill.
Date: October 26th 2019, 8:00 - 18:00
A neglected topic for way too long, the interest in fluid therapy seems to be quickly rising as the medical community is making a shift from looking at fluids as a mere method of stabilization towards the appreciation of its relevant side effects.
Many questions remain to be answered indeed:
Is the upgrade from saline 0.9% to balanced crystalloids worth the extra cost?
Does HES still have a place in the OR?
Do we have to fill the gap left by HES on ICU with crystalloids, other colloids or even albumin?
Is it really impossible to avoid fluid overload by using only crystalloids?
Is there still a definitive place for human albumin?
How do we treat and monitor specific patient populations, like patients with trauma, liver failure, brain edema and right heart failure among others?
How do we avoid a one-size-fits-all regimen in perioperative goal-directed therapy?
What with the fluids beyond resuscitation?
And what do the authors of the big fluid trials do in real life themselves?
The 9th International Fluid Academy Day will again be a 1 day concise meeting on all aspects of fluid managament and hemodynamic monitoring in the critically ill.
Date: October 26th 2019, 8:00 - 18:00
A neglected topic for way too long, the interest in fluid therapy seems to be quickly rising as the medical community is making a shift from looking at fluids as a mere method of stabilization towards the appreciation of its relevant side effects.
Many questions remain to be answered indeed:
Is the upgrade from saline 0.9% to balanced crystalloids worth the extra cost?
Does HES still have a place in the OR?
Do we have to fill the gap left by HES on ICU with crystalloids, other colloids or even albumin?
Is it really impossible to avoid fluid overload by using only crystalloids?
Is there still a definitive place for human albumin?
How do we treat and monitor specific patient populations, like patients with trauma, liver failure, brain edema and right heart failure among others?
How do we avoid a one-size-fits-all regimen in perioperative goal-directed therapy?
What with the fluids beyond resuscitation?
And what do the authors of the big fluid trials do in real life themselves?
The 9th International Fluid Academy Day will again be a 1 day concise meeting on all aspects of fluid managament and hemodynamic monitoring in the critically ill.
Date: October 26th 2019, 8:00 - 18:00
A neglected topic for way too long, the interest in fluid therapy seems to be quickly rising as the medical community is making a shift from looking at fluids as a mere method of stabilization towards the appreciation of its relevant side effects.
Many questions remain to be answered indeed:
Is the upgrade from saline 0.9% to balanced crystalloids worth the extra cost?
Does HES still have a place in the OR?
Do we have to fill the gap left by HES on ICU with crystalloids, other colloids or even albumin?
Is it really impossible to avoid fluid overload by using only crystalloids?
Is there still a definitive place for human albumin?
How do we treat and monitor specific patient populations, like patients with trauma, liver failure, brain edema and right heart failure among others?
How do we avoid a one-size-fits-all regimen in perioperative goal-directed therapy?
What with the fluids beyond resuscitation?
And what do the authors of the big fluid trials do in real life themselves?
The 9th International Fluid Academy Day will again be a 1 day concise meeting on all aspects of fluid managament and hemodynamic monitoring in the critically ill.
Date: October 26th 2019, 8:00 - 18:00
This document discusses fluid responsiveness monitoring during surgery. It begins by outlining parameters used to evaluate fluid responsiveness, such as pulse pressure variation (PPV) and stroke volume variation (SVV). It notes that PPV directly measures pressure changes while SVV estimates volume changes. The document then examines other hemodynamic parameters like arterial elastance and dynamic elastance. It argues that a multiparameter model integrating pressures, perfusion, afterload, flow and dynamic vascular tone can better guide fluid management than any single parameter. The overall message is that fluid assessment during surgery requires considering multiple interconnected physiologic factors.
A neglected topic for way too long, the interest in fluid therapy seems to be quickly rising as the medical community is making a shift from looking at fluids as a mere method of stabilization towards the appreciation of its relevant side effects.
Many questions remain to be answered indeed:
Is the upgrade from saline 0.9% to balanced crystalloids worth the extra cost?
Does HES still have a place in the OR?
Do we have to fill the gap left by HES on ICU with crystalloids, other colloids or even albumin?
Is it really impossible to avoid fluid overload by using only crystalloids?
Is there still a definitive place for human albumin?
How do we treat and monitor specific patient populations, like patients with trauma, liver failure, brain edema and right heart failure among others?
How do we avoid a one-size-fits-all regimen in perioperative goal-directed therapy?
What with the fluids beyond resuscitation?
And what do the authors of the big fluid trials do in real life themselves?
The 9th International Fluid Academy Day will again be a 1 day concise meeting on all aspects of fluid managament and hemodynamic monitoring in the critically ill.
Date: October 26th 2019, 8:00 - 18:00
(1) This document discusses fluid overload in intensive care patients. It defines terms like fluid balance, fluid overload, and approaches to fluid management.
(2) Fluid overload is associated with worse outcomes and can be assessed using clinical signs, biomarkers, hemodynamic parameters, organ function tests, and imaging studies. Persistent positive cumulative fluid balance and signs of generalized increased permeability syndrome indicate the need for de-resuscitation.
(3) De-resuscitation, or late goal-directed fluid removal, can be guided by monitoring changes in parameters like extravascular lung water index, pulmonary vascular permeability index, and intra-abdominal pressure in response to diuretics or renal replacement therapy. The goal
A neglected topic for way too long, the interest in fluid therapy seems to be quickly rising as the medical community is making a shift from looking at fluids as a mere method of stabilization towards the appreciation of its relevant side effects.
Many questions remain to be answered indeed:
Is the upgrade from saline 0.9% to balanced crystalloids worth the extra cost?
Does HES still have a place in the OR?
Do we have to fill the gap left by HES on ICU with crystalloids, other colloids or even albumin?
Is it really impossible to avoid fluid overload by using only crystalloids?
Is there still a definitive place for human albumin?
How do we treat and monitor specific patient populations, like patients with trauma, liver failure, brain edema and right heart failure among others?
How do we avoid a one-size-fits-all regimen in perioperative goal-directed therapy?
What with the fluids beyond resuscitation?
And what do the authors of the big fluid trials do in real life themselves?
The 9th International Fluid Academy Day will again be a 1 day concise meeting on all aspects of fluid managament and hemodynamic monitoring in the critically ill.
Date: October 26th 2019, 8:00 - 18:00
This symposium provides an overview of the (r)evolution in intensive care medicine. The programme is based on lectures of 20 minutes where each speaker presents in two 10 minute talks (in der Beschränkung zeigt sich erst der Meister) the good things that happened in the last 40 years in critical care vs our mistakes or what is missing with respect to that topic. At the end of the session the speakers participate in an interactive round table discussion with online voting to get the audience involved. Will be discussed: Theoretical concepts, basic physiology and pathophysiology, monitoring, and future directions.
This symposium provides an overview of the (r)evolution in intensive care medicine. The programme is based on lectures of 20 minutes where each speaker presents in two 10 minute talks (in der Beschränkung zeigt sich erst der Meister) the good things that happened in the last 40 years in critical care vs our mistakes or what is missing with respect to that topic. At the end of the session the speakers participate in an interactive round table discussion with online voting to get the audience involved. Will be discussed: Theoretical concepts, basic physiology and pathophysiology, monitoring, and future directions.
This symposium provides an overview of the (r)evolution in intensive care medicine. The programme is based on lectures of 20 minutes where each speaker presents in two 10 minute talks (in der Beschränkung zeigt sich erst der Meister) the good things that happened in the last 40 years in critical care vs our mistakes or what is missing with respect to that topic. At the end of the session the speakers participate in an interactive round table discussion with online voting to get the audience involved. Will be discussed: Theoretical concepts, basic physiology and pathophysiology, monitoring, and future directions.
This symposium provides an overview of the (r)evolution in intensive care medicine. The programme is based on lectures of 20 minutes where each speaker presents in two 10 minute talks (in der Beschränkung zeigt sich erst der Meister) the good things that happened in the last 40 years in critical care vs our mistakes or what is missing with respect to that topic. At the end of the session the speakers participate in an interactive round table discussion with online voting to get the audience involved. Will be discussed: Theoretical concepts, basic physiology and pathophysiology, monitoring, and future directions.
This symposium provides an overview of the (r)evolution in intensive care medicine. The programme is based on lectures of 20 minutes where each speaker presents in two 10 minute talks (in der Beschränkung zeigt sich erst der Meister) the good things that happened in the last 40 years in critical care vs our mistakes or what is missing with respect to that topic. At the end of the session the speakers participate in an interactive round table discussion with online voting to get the audience involved. Will be discussed: Theoretical concepts, basic physiology and pathophysiology, monitoring, and future directions.
This symposium provides an overview of the (r)evolution in intensive care medicine. The programme is based on lectures of 20 minutes where each speaker presents in two 10 minute talks (in der Beschränkung zeigt sich erst der Meister) the good things that happened in the last 40 years in critical care vs our mistakes or what is missing with respect to that topic. At the end of the session the speakers participate in an interactive round table discussion with online voting to get the audience involved. Will be discussed: Theoretical concepts, basic physiology and pathophysiology, monitoring, and future directions.
This symposium provides an overview of the (r)evolution in intensive care medicine. The programme is based on lectures of 20 minutes where each speaker presents in two 10 minute talks (in der Beschränkung zeigt sich erst der Meister) the good things that happened in the last 40 years in critical care vs our mistakes or what is missing with respect to that topic. At the end of the session the speakers participate in an interactive round table discussion with online voting to get the audience involved. Will be discussed: Theoretical concepts, basic physiology and pathophysiology, monitoring, and future directions.
About this webinar: This talk will introduce what cancer rehabilitation is, where it fits into the cancer trajectory, and who can benefit from it. In addition, the current landscape of cancer rehabilitation in Canada will be discussed and the need for advocacy to increase access to this essential component of cancer care.
Stem Cell Solutions: Dr. David Greene's Path to Non-Surgical Cardiac CareDr. David Greene Arizona
Explore the groundbreaking work of Dr. David Greene, a pioneer in regenerative medicine, who is revolutionizing the field of cardiology through stem cell therapy in Arizona. This ppt delves into how Dr. Greene's innovative approach is providing non-surgical, effective treatments for heart disease, using the body's own cells to repair heart damage and improve patient outcomes. Learn about the science behind stem cell therapy, its benefits over traditional cardiac surgeries, and the promising future it holds for modern medicine. Join us as we uncover how Dr. Greene's commitment to stem cell research and therapy is setting new standards in healthcare and offering new hope to cardiac patients.
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardso...rightmanforbloodline
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardson, Verified Chapters 1 - 18, Complete Newest Version
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardson, Verified Chapters 1 - 18, Complete Newest Version
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardson, Verified Chapters 1 - 18, Complete Newest Version
Can Allopathy and Homeopathy Be Used Together in India.pdfDharma Homoeopathy
This article explores the potential for combining allopathy and homeopathy in India, examining the benefits, challenges, and the emerging field of integrative medicine.
Hypertension and it's role of physiotherapy in it.Vishal kr Thakur
This particular slides consist of- what is hypertension,what are it's causes and it's effect on body, risk factors, symptoms,complications, diagnosis and role of physiotherapy in it.
This slide is very helpful for physiotherapy students and also for other medical and healthcare students.
Here is summary of hypertension -
Hypertension, also known as high blood pressure, is a serious medical condition that occurs when blood pressure in the body's arteries is consistently too high. Blood pressure is the force of blood pushing against the walls of blood vessels as the heart pumps it. Hypertension can increase the risk of heart disease, brain disease, kidney disease, and premature death.
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
This particular slides consist of- what is Pneumothorax,what are it's causes and it's effect on body, risk factors, symptoms,complications, diagnosis and role of physiotherapy in it.
This slide is very helpful for physiotherapy students and also for other medical and healthcare students.
Here is a summary of Pneumothorax:
Pneumothorax, also known as a collapsed lung, is a condition that occurs when air leaks into the space between the lung and chest wall. This air buildup puts pressure on the lung, preventing it from expanding fully when you breathe. A pneumothorax can cause a complete or partial collapse of the lung.
Chandrima Spa Ajman is one of the leading Massage Center in Ajman, which is open 24 hours exclusively for men. Being one of the most affordable Spa in Ajman, we offer Body to Body massage, Kerala Massage, Malayali Massage, Indian Massage, Pakistani Massage Russian massage, Thai massage, Swedish massage, Hot Stone Massage, Deep Tissue Massage, and many more. Indulge in the ultimate massage experience and book your appointment today. We are confident that you will leave our Massage spa feeling refreshed, rejuvenated, and ready to take on the world.
Visit : https://massagespaajman.com/
Call : 052 987 1315
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to CareVITASAuthor
This webinar helps clinicians understand the unique healthcare needs of the LGBTQ+ community, primarily in relation to end-of-life care. Topics include social and cultural background and challenges, healthcare disparities, advanced care planning, and strategies for reaching the community and improving quality of care.
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
Dr. David Greene R3 stem cell Breakthroughs: Stem Cell Therapy in CardiologyR3 Stem Cell
Dr. David Greene, founder and CEO of R3 Stem Cell, is at the forefront of groundbreaking research in the field of cardiology, focusing on the transformative potential of stem cell therapy. His latest work emphasizes innovative approaches to treating heart disease, aiming to repair damaged heart tissue and improve heart function through the use of advanced stem cell techniques. This research promises not only to enhance the quality of life for patients with chronic heart conditions but also to pave the way for new, more effective treatments. Dr. Greene's work is notable for its focus on safety, efficacy, and the potential to significantly reduce the need for invasive surgeries and long-term medication, positioning stem cell therapy as a key player in the future of cardiac care.
Gemma Wean- Nutritional solution for Artemiasmuskaan0008
GEMMA Wean is a high end larval co-feeding and weaning diet aimed at Artemia optimisation and is fortified with a high level of proteins and phospholipids. GEMMA Wean provides the early weaned juveniles with dedicated fish nutrition and is an ideal follow on from GEMMA Micro or Artemia.
GEMMA Wean has an optimised nutritional balance and physical quality so that it flows more freely and spreads readily on the water surface. The balance of phospholipid classes to- gether with the production technology based on a low temperature extrusion process improve the physical aspect of the pellets while still retaining the high phospholipid content.
GEMMA Wean is available in 0.1mm, 0.2mm and 0.3mm. There is also a 0.5mm micro-pellet, GEMMA Wean Diamond, which covers the early nursery stage from post-weaning to pre-growing.
Unlocking the Secrets to Safe Patient Handling.pdfLift Ability
Furthermore, the time constraints and workload in healthcare settings can make it challenging for caregivers to prioritise safe patient handling Australia practices, leading to shortcuts and increased risks.
6. Maas AI et al. The Lancet Neurology 2008
Macrovascular
Microvascular
Molecular
Importance of differential pathophysiological mechanisms
STRUCTURE
Microvascular
Molecular
Inflammation
Receptor-mediated damage
Oxidative damage
Calcium-mediated damage
7. Dynamic and
PROGRESSIVE
process following
injury
Adapted from Stocchetti N et al. Crit Care 2013
Excitotoxicity
Edema
Mitochondrial dysfunction
Impaired oxygen diffusion
Impaired autoregulation, reduced CBF
Energy dysfunction
Hours Days
Inflammation
Cortical depolarizations
Neurodegeneration
TIME
Importance of differential pathophysiological mechanisms
8. Neuroprotective agents
• The focus for neuroprotective strategies has
mostly been on pharmacological agents
• Preliminary results of these agents were often
encouraging
• Unfortunately, clinical trials using these candidate
neuroprotective agents have consistently
produced disappointing results
• To date, there is no targeted pharmacological
treatment that effectively limits the progression of
secondary injury
SYNAPSE
EPO-TBI
PEG-SOD
Tirilazad
Selfotel
Traxoprodil
Dexanabinol
Magnesium Sulfate
COBRIT
Perhaps deflected attention from the
development of neuroprotective
strategies and trials addressing
everyday ICU management
9. Outcomes improving over time
• Despite repeated failures in pharmacological neuroprotection,
outcomes for TBI patients have improved
• Secular trend in general critical care organization and delivery of care
improvements over the past 2 decades
• Likely that the organization of intensive treatment has contributed,
offering a different kind of neuroprotection based on careful
prevention and limitation of intracranial and systemic threats
Kramer & Zygun. Can J Anesth 2013 Oct;60(10):966-75
Rosenfeld et al. Lancet. 2012 Sep 22;380(9847)
10. Outline
The importance of neuroprotection
Secondary brain injury targets
Neuroprotection at the bedside
15. Pressure*time burden of intracranial
hypertension
Güiza F et al Intensive Care Med. 2015 Jun;41(6):1067-76
ICP
‘dose’Increasing
time spent at
ICP level
ICP value
Worse
outcome
19. • Recommended target CPP for survival and favorable
outcomes between 60-70 mmHg
• Unclear whether 60 or 70 mm Hg is the minimum optimal
CPP threshold
• May depend upon the patient’s autoregulatory status
https://www.braintrauma.org/guidelines/guidelines-for-the-management-of-severe-tbi-4th-ed#/:guideline/17-cerebral-perfusion-pressure-thresholds
Cerebral perfusion pressure thresholds
20. Assessment of cerebral autoregulation state
All comers
ICP 20mmHg
30 mins
Ability to
tolerate burden
of intracranial
hypertension
Güiza F et al Intensive Care Med. 2015 Jun;41(6):1067-76
22. CA disrupted
ICP 20mmHg
15 mins
Assessment of cerebral autoregulation state
INABILITY to
tolerate burden
of intracranial
hypertension
Güiza F et al Intensive Care Med. 2015 Jun;41(6):1067-76
24. Are these two patients different?
ICP 23 ICP 21
PATIENT A PATIENT B
Meyfroidt & Citerio. Neurosurgery 2017 Jul 1;81(1):E1
25. Which patient are you more concerned about now?
ICP 23
ICP 21
ICP 9
PATIENT A PATIENT B
Meyfroidt & Citerio. Neurosurgery 2017 Jul 1;81(1):E1
26. Outline
The importance of neuroprotection
Secondary brain injury targets
Neuroprotection at the bedside
27. Neuroprotection at the bedside
Detection of secondary insults
at the bedside
1
Translation of neuroprotective
strategies at the bedside
2
Integrated neurophysiologic
monitoring
Standardized management protocol
28. Neuroprotection at the bedside
Detection of secondary insults
at the bedside
1
Translation of neuroprotective
strategies at the bedside
2
Integrated neurophysiologic
monitoring
Standardized management protocol
29. Why is neurological monitoring so important?
1. First 48 hours, up to 40% of TBI
patients show a clinically relevant
neurological worsening
2. NO neurological deterioration vs
neurological deterioration:
• Mortality rate of 9.6% vs 56.4%
• Favorable outcome of 67.8% vs 29.1%
Brown et al. J Trauma 2007 Jun;62(6):1339-44 Iaccarino et al. J Neurosurg 2014 Apr;120(4):908-18
Juul et al. J Neurosurg 2000 Jan;92(1):1-6 Maas et al. Lancet Neurol 2006 Jan;5(1):38-45
Morris et al. Neurosurgery 1998 Dec;43(6):1369-72
Reasons for neurological deterioration:
1. Increased intracranial volume 63.4%
2. Systemic complications 12.5%
3. No definable cause 12.5%
4. Seizures 6.7%
5. Cerebral ischemia 4.8%
30. Day 2 ICU TBI
• 42 year old male
• Severe TBI
• GCS E1 M4 VT
• Brainstem reflexes intact
• Sedated for ICP/brain
protective ventilation
31. How do we detect secondary
brain insults in this comatose
patient?
34. Reduction in brain tissue hypoxia burden
ICP only
PbtO2 and ICP
Tiered PbtO2 management
• Decreased total duration of
hypoxia by 66%
• Decreased average depth of
hypoxia by 72%
• Reduced area under the curve
by 77%Total hypoxia burden (hrs * mmHg)
35. It remains to be demonstrated whether
multimodal monitoring-guided therapy is
able to improve outcome.
36. Neuroprotection at the bedside
Detection of secondary insults
at the bedside
1
Translation of neuroprotective
strategies at the bedside
2
Integrated neurophysiologic
monitoring
Standardized management protocol
38. How can protocols improve patient care?
• Aims to improve outcomes by guiding consistent patient care:
1. Facilitate communication
2. Reduce cognitive load
3. Coordinate the interdisciplinary team
4. Increase the adoption of evidence-based interventions and
improve adherence to guidelines
Chang et al. Critical Care 2012
39. Neurocritical care interventions
ICU STRUCTURE:
DEDICATED NCC UNITS VS
GENERAL ICU
PROCESS OF CARE:
PRESENCE OF A
STANDARDIZED TBI
MANAGEMENT PROTOCOL
McCredie et al. Crit Care Med. 2018 Jul;46(7):1139-1149
ICP
PbrO2
40. Results
Dedicated neurocritical care
units were not associated with
lower risk-adjusted in-hospital
mortality
aOR 0.97 (95% CI 0.80-1.19)
Standardized management
protocols were associated with
improved in-hospital mortality
aOR 0.77 (95% CI 0.63-0.93)
McCredie et al. Crit Care Med. 2018 Jul;46(7):1139-1149
41. In conclusion
• Our understanding of secondary brain injury mechanisms and physiologic
responses to treatment is continually evolving
• Moving forward, we must better understand whether these neurophysiologic
parameters are modifiable, and whether modification affects relevant outcomes
• Neurophysiologic monitoring at the bedside is a DYNAMIC process, not a single
measurement
• Integrated neuromonitoring may improve situational awareness and allow an
individualized approach to therapy